SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

 

03 November 2008

 

 

PROTHERICS PLC

(Translation of Registrant’s Name Into English)

 

 

The Heath Business & Technical Park
Runcorn, Cheshire, W47 4QF England

(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F       X              Form 40-F               

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):             

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 191(b)(7):             

 

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
            under the Securities Exchange Act of 1934.

 

Yes                     No          X     

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-              .

 

 

The Registrant is furnishing a copy of its announcements as reported to the Company Announcements Office of the London Stock Exchange.

 

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

       

 

PROTHERICS PLC

       

Date: 03 November 2008

 

By:

 

/s/ Rolf Soderstrom


       

Rolf Soderstrom

       

Finance Director

 

Protherics PLC

Total Voting Rights and Share Capital


London, UK; Brentwood, TN; 3 November 2008 -  In conformity with the Transparency Directive,  Protherics PLC ("Protherics"), the international biopharmaceutical company focused on critical care and cancer, notifies the market of the following:

Protherics' issued share capital consists of 350,427,481 ordinary shares with a nominal value of 2 pence each, with voting rights. Protherics does not hold any ordinary shares in Treasury.  Therefore, the total number of voting rights in Protherics is 350,427,481.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Protherics under the Financial Services Authority's Disclosure and Transparency Rules.


| Ends |



For further information please contact:

Protherics 


Nick Staples, Director of Corporate Affairs

                       +44 (0) 7919 480510  

Julie Vickers, Company Secretary     

                       +44 (0)1928 518010

 

 

Financial Dynamics  - press enquiries

 

London: Ben Atwell, Lara Mott

                       +44 (0) 20 7831 3113 

New York: John Capodanno

                       +1 212 850 5600


Or visit   www.protherics.com

Protherics (NASDAQ:PTIL)
Historical Stock Chart
Von Mai 2024 bis Jun 2024 Click Here for more Protherics Charts.
Protherics (NASDAQ:PTIL)
Historical Stock Chart
Von Jun 2023 bis Jun 2024 Click Here for more Protherics Charts.